Crinetics Pharmaceuticals, Inc. (CRNX)
收市後：
| 前收市價 | 43.49 |
| 開市 | 43.73 |
| 買盤 | 43.97 x 300 |
| 賣出價 | 44.07 x 300 |
| 今日波幅 | 43.28 - 44.31 |
| 52 週波幅 | 15.76 - 49.58 |
| 成交量 | |
| 平均成交量 | 817,714 |
| 市值 | 3.43B |
| Beta 值 (5 年，每月) | 0.62 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.69 |
| 業績公佈日 | 2024年5月02日 - 2024年5月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 57.92 |
ZacksBiotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.
ZacksCrinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
Crinetics Pharmaceuticals (CRNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
BenzingaEndocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
Tuesday, Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) released topline results from PATHFNDR-2, the second of two Phase 3 studies evaluating the efficacy and safety of paltusotine for acromegaly. Acromegaly is a hormonal disorder that develops when the pituitary gland produces too much growth hormone during adulthood. The 111-participant study met statistical significance (p<0.0001) on the primary endpoint, based on the proportion of participants taking paltusotine (56%) who achieved an insulin-l
